U.S. markets open in 9 hours 1 minute
  • S&P Futures

    4,432.50
    -0.50 (-0.01%)
     
  • Dow Futures

    34,784.00
    +41.00 (+0.12%)
     
  • Nasdaq Futures

    15,157.25
    -37.50 (-0.25%)
     
  • Russell 2000 Futures

    2,281.80
    +4.80 (+0.21%)
     
  • Crude Oil

    76.12
    +0.67 (+0.89%)
     
  • Gold

    1,749.70
    -2.30 (-0.13%)
     
  • Silver

    22.62
    -0.07 (-0.33%)
     
  • EUR/USD

    1.1697
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.4840
    -1.4600 (-100.00%)
     
  • Vix

    18.76
    -17.75 (-100.00%)
     
  • GBP/USD

    1.3708
    +0.0004 (+0.03%)
     
  • USD/JPY

    111.1680
    +0.1900 (+0.17%)
     
  • BTC-USD

    42,740.04
    -1,313.61 (-2.98%)
     
  • CMC Crypto 200

    1,059.17
    -42.34 (-3.84%)
     
  • FTSE 100

    7,063.40
    +11.92 (+0.17%)
     
  • Nikkei 225

    30,104.88
    -135.18 (-0.45%)
     

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ATER, DNMR and ATHA

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / July 5, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Aterian, Inc. (NASDAQ:ATER)

Investors Affected : December 1, 2020 - May 3, 2021

A class action has commenced on behalf of certain shareholders in Aterian, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's organic growth is plummeting; (ii) the Company's recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources; (iii) Aterian's purported artificial intelligence software is a flawed product that lacks customer interest; (iv) Aterian uses rebate programs and paid or artificial reviews to pump up their product offerings; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/aterian-inc-loss-submission-form/?id=17392&from=1

Danimer Scientific, Inc. (NYSE:DNMR)

Investors Affected : October 5, 2020 - May 4, 2021

A class action has commenced on behalf of certain shareholders in Danimer Scientific, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Danimer had deficient internal controls; (ii) as a result, the Company had misrepresented, inter alia, its operations' size and regulatory compliance; (iii) Defendants had overstated Nodax's biodegradability, particularly in oceans and landfills; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/danimer-scientific-inc-loss-submission-form/?id=17392&from=1

Athira Pharma, Inc. (NASDAQ:ATHA)

This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.

A class action has commenced on behalf of certain shareholders in Athira Pharma, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.

Shareholders may find more information at https://securitiesclasslaw.com/securities/athira-pharma-inc-loss-submission-form/?id=17392&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/654253/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-ATER-DNMR-and-ATHA